EQ

Insider Trades

Name	Value	Action	Price	Current Price
Connelly StephenPresident And CSO $91k31k shares SellJun 5, 2026 $2.94 --
Zedelmayer ChristineSr. Vice President And COO $43k14.6k shares SellJun 5, 2026 $2.93 --
Connelly StephenPresident And CSO $633k200k shares SellJun 4, 2026 $3.16 --
Zedelmayer ChristineSr. Vice President And COO $542200 shares SellMay 28, 2026 $2.71 --
Tom PennyPrincipal Accounting Officer $192k65k shares SellMay 28, 2026 $2.95 --
Zedelmayer ChristineSr. Vice President And COO $150k55.6k shares SellMay 28, 2026 $2.70 --

News

globenewswire.comEquillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.comJun 2

seekingalpha.comEquillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammatory Disease Transcriptseekingalpha.comJun 1

marketbeat.comEquillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1marketbeat.comMay 29

globenewswire.comEquillium to Participate in the 2026 Jefferies Global Healthcare Conferenceglobenewswire.comMay 28

globenewswire.comEquillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axisglobenewswire.comMay 20

Trade EQ

About Equillium, Inc.

Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.

CEO: Bruce D. Steel
IPO Date: Oct 12, 2018

Market Data

Open: $2.80
High: $2.97
Low: $2.62
Volume: 433.2K
52W High: $3.45
52W Low: $0.27

Valuation

Market Cap: $96M
Enterprise Value: $35M

Financials

Free Cash Flow: $-23M
Revenue: $0
Net Income: $-22M
Cash: $30M
Debt: $719k

Events

EarningsAug 13

EPS est. -0.05